002907.SZ深圳证券交易所 · 主板 Main
Chongqing Pharscin Pharmaceutical 华森制药
Traditional Chinese Medicine 中药Ⅱ
¥14.49+¥0.06 · +0.42%
Open 开盘
¥14.73
High 最高
¥14.73
Low 最低
¥14.35
Prev Close 昨收
¥14.43
Volume 成交量
1,030.1万股
Turnover 成交额
¥1.49亿
Mkt Cap 总市值
¥61亿
P/E 市盈率
81.6×
Recent Activity 近期动态All Filings 全部公告 →
5 significant filings since 31 May 2026: 2 on acquisition or disposal, 1 on dividend and 1 on major holder selling, and 1 other kind. The latest, on 23 Sep 2026: 关于公司全资子公司受让成都华森奥睿药业有限公司股权的进展公告.
自 31 May 2026 起有 5 份重大公告：acquisition or disposal 2 份、dividend 1 份、major holder selling 1 份，另有 1 类。最新一份（23 Sep 2026）：关于公司全资子公司受让成都华森奥睿药业有限公司股权的进展公告。
Price History 价格走势
250 trading days 个交易日 · High 最高 ¥17.27 · Low 最低 ¥11.6612.0013.0014.0015.0016.0017.00
Volume 成交量
5,350.3万
Sep 25Dec 25Mar 26Jul 26Sep 26
Overview 概览Deep Report 深度报告Financials 财务Valuation 估值Ownership 股东Analysts 券商Estimates 预测News 动态Events 事件Peers 同业
Relative Value 同业比较
Traditional Chinese Medicine 中药Ⅱ · 66 listed peers
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥61亿 | ¥60亿 | 33rd highest of 66 · 66 家中第 33 高 | |
| Trailing P/E 市盈率 | 81.6x | 31.9x | 13th highest of 49 · 49 家中第 13 高 | |
| P/B 市净率 | 3.5x | 2.2x | 16th highest of 65 · 65 家中第 16 高 | |
| Revenue Growth 营收增速 | -6.4% | -7.4% | 30th highest of 66 · 66 家中第 30 高 | |
| Profit Growth 净利增速 | 16.7% | -0.2% | 17th highest of 66 · 66 家中第 17 高 | |
| Gross Margin 毛利率 | 59.3% | 56.9% | 28th highest of 66 · 66 家中第 28 高 | |
| Net Margin 净利率 | 13.5% | 9.6% | 24th highest of 66 · 66 家中第 24 高 | |
| Return on Equity 净资产收益率 | 3.7% | 3.0% | 32nd highest of 65 · 65 家中第 32 高 | |
| Debt to Assets 资产负债率 | 14.8% | 28.4% | 9th lowest of 66 · 66 家中第 9 低 | |
| Grade Score 评级得分 | 62 | 52 | 21st highest of 66 · 66 家中第 21 高 |
Statement figures are for the period to 30 Jun 2026, filed by 66 of 66 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，66 家同业中 66 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
Largest Peers 主要同业
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Yunnan Baiyao Group 云南白药 | ¥898亿 | 17.2x | 2.2x | 2.9% | 16.9% | 9.0% | C |
| Zhangzhou Pientzehuang Pharmaceutical 片仔癀 | ¥704亿 | 38.9x | 4.8x | -15.0% | 23.7% | 7.3% | C |
| China Resources Sanjiu Medical 华润三九 | ¥391亿 | 11.9x | 1.7x | 1.4% | 13.3% | 7.3% | C |
| Beijing Tong Ren Tang 同仁堂 | ¥320亿 | 33.0x | 2.3x | -14.2% | 11.2% | 5.2% | D |
| Guangzhou Baiyunshan Pharmaceutical Holdings 白云山 | ¥316亿 | 12.3x | 0.8x | 0.6% | 5.1% | 5.4% | D |
| Dong-E-E-Jiao 东阿阿胶 | ¥290亿 | 16.2x | 2.9x | 3.4% | 27.3% | 8.1% | C |
| Tianjin Pharmaceutical Da Ren Tang 达仁堂 | ¥271亿 | 31.9x | 4.6x | -7.4% | 26.2% | 9.1% | C |
| Shijiazhuang Yiling Pharmaceutical 以岭药业 | ¥253亿 | 18.4x | 2.3x | 0.9% | 18.6% | 6.7% | B |
| Jumpcan 济川药业 | ¥227亿 | 12.4x | 1.6x | -15.3% | 33.6% | 5.3% | C |
| Tasly 天士力 | ¥206亿 | 16.9x | 1.6x | -2.0% | 21.1% | 7.0% | C |
| Jilin Aodong Pharmaceutical Group 吉林敖东 | ¥206亿 | 6.5x | 0.6x | -8.5% | 198.7% | 6.5% | C |
| Guangdong Zhongsheng Pharmaceutical 众生药业 | ¥196亿 | 98.6x | 4.9x | -23.0% | 10.7% | 2.7% | C |
| Kangmei Pharmaceutical 康美药业 | ¥183亿 | 619.6x | 2.5x | -11.1% | 1.6% | 0.5% | D |
| Buchang Pharma 步长制药 | ¥153亿 | 64.8x | 1.5x | -11.7% | 9.2% | 4.9% | D |
| Chongqing Pharscin Pharmaceutical 华森制药 | ¥61亿 | 81.6x | 3.5x | -6.4% | 13.5% | 3.7% | C |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。